Summit Global Investments Purchases 313,642 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)

Summit Global Investments raised its position in Takeda Pharmaceutical Company Limited (NYSE:TAK) by 75.5% in the 4th quarter, Holdings Channel reports. The firm owned 729,200 shares of the company’s stock after buying an additional 313,642 shares during the period. Summit Global Investments’ holdings in Takeda Pharmaceutical were worth $9,655,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Versant Capital Management Inc bought a new stake in Takeda Pharmaceutical in the fourth quarter valued at approximately $26,000. Wilmington Savings Fund Society FSB bought a new stake in Takeda Pharmaceutical in the third quarter valued at approximately $40,000. BNP Paribas Financial Markets increased its stake in Takeda Pharmaceutical by 416.0% in the third quarter. BNP Paribas Financial Markets now owns 3,220 shares of the company’s stock valued at $46,000 after purchasing an additional 2,596 shares in the last quarter. Farther Finance Advisors LLC increased its stake in Takeda Pharmaceutical by 123.6% in the fourth quarter. Farther Finance Advisors LLC now owns 3,575 shares of the company’s stock valued at $47,000 after purchasing an additional 1,976 shares in the last quarter. Finally, Smithfield Trust Co increased its stake in Takeda Pharmaceutical by 76.9% in the third quarter. Smithfield Trust Co now owns 3,428 shares of the company’s stock valued at $49,000 after purchasing an additional 1,490 shares in the last quarter. Institutional investors own 9.17% of the company’s stock.

Takeda Pharmaceutical Stock Up 0.2 %

Shares of NYSE:TAK opened at $15.20 on Friday. The company has a 50 day moving average price of $13.96 and a two-hundred day moving average price of $13.92. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.72 and a current ratio of 1.31. Takeda Pharmaceutical Company Limited has a 52 week low of $12.58 and a 52 week high of $15.31. The company has a market capitalization of $48.35 billion, a PE ratio of 37.99, a PEG ratio of 0.24 and a beta of 0.46.

Takeda Pharmaceutical (NYSE:TAK) last issued its quarterly earnings data on Thursday, January 30th. The company reported $0.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.34 by $0.08. Takeda Pharmaceutical had a net margin of 4.53% and a return on equity of 9.39%. Analysts forecast that Takeda Pharmaceutical Company Limited will post 1.64 earnings per share for the current year.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.